Assessing the cost of parathyroidectomy as a treatment for uncontrolled secondary hyperparathyroidism in stage 5 chronic kidney disease
posterposted on 25.02.2020 by James Fotheringham, Alejandra Duenas, Andrew Rawdin, Martin Wilkie, B. Harrison, Ronald Akehurst
Poster sessions are particularly prominent at academic conferences. Posters are usually one frame of a powerpoint (or similar) presentation and are represented at full resolution to make them zoomable.
Conventional therapy for chronic kidney disease mineral bone disorder includes control of serum phosphate with phosphate binders and the supplementation of activated vitamin D. In many cases this proves inadequate, and in the UK parathyroidectomy (PTX) is recommended for patients who are otherwise surgical fit as it is perceived as less costly than calcimemetics. However, no details of the true cost of PTX have been published. AIMS: To describe the healthcare resource use and costs associated with patients receiving PTX as a treatment for uncontrolled secondary hyperparathyroidism in a single UK National Health Service (NHS) centre (Sheffield Kidney Institute).
EthicsThere is no personal data or any that requires ethical approval
PolicyThe data complies with the institution and funders' policies on access and sharing
Sharing and access restrictionsThe data can be shared openly
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files